Halozyme Therapeutics, Inc. EPS (Earnings per Share) 2009–2025
Halozyme Therapeutics, Inc. reported $2.56 of earnings per share for fiscal 2025. That was 25.4% lower than fiscal 2024. Compared with fiscal 2020, the change was +181.3%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $2.56 | -25.4% |
| FY 2024 | $3.43 | +63.3% |
| FY 2023 | $2.10 | +45.8% |
| FY 2022 | $1.44 | -47.4% |
| FY 2021 | $2.74 | +201.1% |
| FY 2020 | $0.91 | +282.0% |
| FY 2019 | $-0.50 | +10.7% |
| FY 2018 | $-0.56 | -224.4% |
| FY 2017 | $0.45 | +155.6% |
| FY 2016 | $-0.81 | -224.0% |
| FY 2015 | $-0.25 | — |
| FY 2014 | $0.00 | — |
| FY 2013 | $0.00 | — |
| FY 2012 | $0.00 | — |
| FY 2011 | $0.00 | — |
| FY 2010 | $0.00 | — |
| FY 2009 | $0.00 | — |
Source: Halozyme Therapeutics, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported $2.56 of earnings per share for fiscal 2025. That was 25.4% lower than fiscal 2024. Compared with fiscal 2020, the change was +181.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s earnings per share?
Halozyme Therapeutics, Inc. (HALO) reported earnings per share of $2.56 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.